Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor natural killer therapy CTH-401 for ovarian cancer, and to expand its pipeline to include other diseases.
Mestag Therapeutics Ltd. has sealed a potential $1.9 billion agreement with Merck & Co. Inc., in which it will apply its expertise in activated fibroblasts to identify novel targets for inflammatory diseases. The pharma company has the option to license one or more targets, up to a prespecified number, and will take on all subsequent discovery, development and commercialization work.
Wuhan YZY Biopharma Co. Ltd. is out-licensing lead candidate M-701, a CD3/EpCAM bispecific antibody, to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) for China rights in a deal worth up to $143 million. Under the deal, Sino Biopharmaceutical Ltd. subsidiary CTTQ is granted an exclusive license to develop, register, manufacture and commercialize M-701 within mainland China.
GE Healthcare Technologies Inc. is participating in the €25.3 million (US$27.8 million) Thera4care project that aims to expand the use of theranostics in Europe. The 29 partners involved in the project will develop new cancer treatment tools, strengthen the manufacture and supply of radiotheranostic, and optimize the clinical use of radiotheranostics.
Betta Pharmaceuticals Co. Ltd. has prepared and tested probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer.
Work at Dark Blue Therapeutics Ltd. has led to the identification of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a MLLT1- or MLLT3-targeting moiety through a linker.
Bayer Consumer Care AG has disclosed new tachykinin NK1 and NK3 receptor dual antagonists reported to be useful for the treatment of breast cancer, endometriosis, hidradenitis, hypertrichosis, osteoporosis, polycystic ovary syndrome, preeclampsia and benign prostatic hyperplasia, among others.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have jointly patented acylsulfonamide histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
In research conducted at West China Hospital of Sichuan University and Chengdu University of Traditional Chinese Medicine, coupling of the pan-FGFR inhibitor erdafitinib with a CRBN binder led to a new series of fibroblast growth factor receptor (FGFR) degraders, with compound [I] identified as the lead candidate.
Investigators at Nanjing Medical University and The University of Texas MD Anderson Cancer Center recently published data from their research that aimed to identify novel immunotherapy targets in triple-negative breast cancer (TNBC).
RSS
